FDA Approves Maintenance Combo for Small Cell Lung Cancer

(MedPage Today) — The FDA approved lurbinectedin (Zepzelca) plus either atezolizumab (Tecentriq) or atezolizumab and hyaluronidase (Tecentriq Hybreza) as first-line maintenance therapy for extensive-stage small cell lung cancer, the agency announced…

Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/117793

Author :

Publish date : 2025-10-03 19:18:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

FDA Approves Maintenance Combo for Small Cell Lung Cancer

FDA Approves Lurbinectedin Combo for ES-SCLC Maintenance

Missed Mammogram Warning; NCI Chief Installed; ‘Father of Palliative Care’ Dies

Related Posts

Pick GLP-1s as First Drug Option in Obesity, Guidelines From Abroad Say

Ahead of Shutdown, Most Americans Said They Wanted ACA Tax Credits Extended

Medical Groups Call for Physician Exemptions to Trump’s Executive Order

Chronic Back Pain in Seniors May Ease With Acupuncture

Missed Mammogram Warning; NCI Chief Installed; ‘Father of Palliative Care’ Dies

FDA Approves Lurbinectedin Combo for ES-SCLC Maintenance

Pick GLP-1s as First Drug Option in Obesity, Guidelines From Abroad Say

Ahead of Shutdown, Most Americans Said They Wanted ACA Tax Credits Extended

Medical Groups Call for Physician Exemptions to Trump’s Executive Order

Chronic Back Pain in Seniors May Ease With Acupuncture

Missed Mammogram Warning; NCI Chief Installed; ‘Father of Palliative Care’ Dies

FDA Approves Maintenance Combo for Small Cell Lung Cancer

FDA Approves Lurbinectedin Combo for ES-SCLC Maintenance

Benefit of Dual Antiplatelet Therapy Murky in Valve-in-Valve Intervention

Categories

Archives